A specially-designed home-based temperature-sensing mat predicted up to 90 percent of non-acute plantar diabetic foot ulcer (DFU) 5 weeks before it manifested clinically, reported researchers at the American Diabetes Association’s (ADA) 76th Scientific Sessions held recently in New Orleans, Louisiana, US.
Pioglitazone reduces the risk of diabetes in nondiabetic, insulin resistant individuals with cerebrovascular disease particularly those with prediabetes, according to a study presented at the 76th Scientific Sessions of the American Diabetes Association held in New Orleans, Louisiana, US.
Energy efficient ketone bodies could be the potential explanation for the positive cardiorenal benefits seen in type 2 diabetes mellitus (T2DM) patients of the EMPA-REG OUTCOME* study, hypothesized researchers at the 76th Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, Louisiana, US.
Nearly 4 years of intensive glycaemic control in patients with type 2 diabetes (T2D) reduces retinopathy progression for up to 4 years after stopping treatment, the ACCORDION* study has shown, a phenomenon researchers described as a “legacy effect.”
The American Diabetes Association’s (ADA) President Desmond Schatz challenged the scientific community to transform diabetes from an invisible disease to a highly visible crisis. “Diabetes is an epidemic spiralling out of control across this country and around the world, yet it remains largely invisible,” he said, speaking at the 76th Scientific Sessions of ADA in New Orleans, Louisiana, US.
Alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, did not increase the risk of cardiovascular (CV)-related death or nonfatal CV events in type 2 diabetes (T2D) patients with recent acute coronary syndrome (ACS) compared with placebo, according to a post-hoc analysis of the EXAMINE* trial presented at the American Diabetes Association’s (ADA) 76th Scientific Sessions held recently in New Orleans, Louisiana, US.
The American Diabetes Association (ADA) and IBM Watson Health announced a long-term partnership to turn the ADA’s repository of diabetes data into insights and digital applications that will benefit scientists, clinicians, diabetes patients, and caregivers during the Association’s 76th Scientific Sessions in New Orleans, Louisiana, US.
Empagliflozin significantly delays the progression of kidney disease and reduces renal events in patients with type 2 diabetes mellitus (T2DM) at high cardiovascular (CV) risk, new data from the EMPA-REG OUTCOME (Empagliflozin-Renal Excretion of Glucose Outcome) trial have shown.
Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated significant reductions in major adverse cardiac events (MACE) in patients with type 2 diabetes mellitus (T2DM) at high cardiovascular (CV) risk in the LEADER (Liraglutide Effect and Action in Diabetes – Evaluation of Cardiovascular Outcomes Results) trial.
A fully automated bionic pancreas delivering insulin and glucagon with an autonomously adaptive dosing algorithm is to begin pivotal trial in the first half of 2017 after promising results from a randomized study in patients with type 1 diabetes mellitus (T1DM).
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.
Empagliflozin treatment in patients with type 2 diabetes mellitus exerts beneficial effects on cardiovascular (CV) risk factors, including blood pressure and uric acid, according to a systematic review and meta-analysis.
A 10 or 20 mg/kg daily dose of cannabidiol could almost halve the risk of seizures in children with Dravet syndrome, according to the phase III GWPCARE2* study presented at the American Academy of Neurology annual meeting (AAN 2019).